LTI-03 is a drug product that addresses Idiopathic Pulmonary Fibrosis. The product is currently in preclinical development, having received both public and private funding. LTI-03 has been shown to resolve bleomycin-induced lung injury when given at 7 or 14 days after the induction of injury, and has the potential to restore healthy lung function in patients suffering from the disease. The compound is thought to address a different cellular pathway than other pharmaceutical approaches, sustaining the survival of alveolar epithelial cells.
LTI-03 has also shown promise in other models of fibrotic diseases.
LTI-01 is being developed for loculated pleural effusions. The compound has undergone significant research and pre-clinical development under several grants from the National Institutes of Health (NIH) and other programs totaling more than $17 million in funding specifically for LTI-01. LTI-01 is planned to enter Phase I clinical trials in 2016. The active pharmaceutical ingredient is a proenzyme, or zymogen, which slowly becomes activated in the pleural space surrounding the lungs. Early studies suggest that the compound effectively clears scar tissue and promotes fluid drainage around the lungs with once-a-day dosing and without bleeding risks or the complications of surgery. The product also was shown to be safe and effective in studies to date.
Lung Therapeutics has received orphan drug designation from both the FDA and the European Commission for LTI-01 in the treatment of empyema. Read the press release.